# üìä Exploratory Data Analysis Report
## Novartis Datathon 2025 - Generic Erosion Forecasting

**Generated:** November 28, 2025  
**Dataset:** 93,744 observations √ó 11 features  
**Brands:** 1,953 unique brands across 54 countries  
**Time Range:** Months -24 to +23 (relative to generic entry)

---

## üìã Table of Contents

1. [Executive Summary](#1-executive-summary)
2. [Dataset Overview](#2-dataset-overview)
3. [Bucket Distribution Analysis](#3-bucket-distribution-analysis)
4. [Erosion Curves by Bucket](#4-erosion-curves-by-bucket)
5. [Competition Impact Analysis](#5-competition-impact-analysis)
6. [Therapeutic Area Analysis](#6-therapeutic-area-analysis)
7. [Biological vs Small Molecule](#7-biological-vs-small-molecule)
8. [Hospital Rate Impact](#8-hospital-rate-impact)
9. [Erosion Speed Metrics](#9-erosion-speed-metrics)
10. [Key Patterns & Insights](#10-key-patterns--insights)
11. [Data Preprocessing Recommendations](#11-data-preprocessing-recommendations)
12. [Feature Engineering Recommendations](#12-feature-engineering-recommendations)
13. [Modeling Recommendations](#13-modeling-recommendations)

---

## 1. Executive Summary

### üéØ Key Findings

| Metric | Value | Implication |
|--------|-------|-------------|
| **Bucket 1 (High Erosion)** | 6.7% of brands (130) | Minority class but **2√ó weight** in evaluation |
| **Bucket 2 (Low Erosion)** | 93.3% of brands (1,823) | Majority class, normal weight |
| **Imbalance Ratio** | 14:1 | Severe class imbalance |
| **Bucket 1 Total Erosion** | 88.27% volume loss | From 0.65 to 0.08 normalized |
| **Bucket 2 Total Erosion** | 40.17% volume loss | From 0.86 to 0.52 normalized |
| **Competition at Entry** | 2.04 generics avg | Doubles to ~4.24 by month 23 |

### ‚ö†Ô∏è Critical Observations

1. **Class Imbalance is SEVERE**: Only 6.7% of brands are Bucket 1, but they carry 2√ó weight
2. **Early Months Matter Most**: Bucket 1 brands lose 65%+ volume in first 6 months
3. **Competition Builds Gradually**: Generic competitors double over 24 months
4. **Therapeutic Area Matters**: Anti-infectives erode fastest, Sensory organs slowest
5. **Hospital Rate Impact**: High hospital rate (75-100%) shows faster erosion

---

## 2. Dataset Overview

### 2.1 Data Dimensions

```
Shape: 93,744 rows √ó 11 columns
Total unique brands: 1,953
Countries: 54
Months range: -24 to +23 (pre-entry to post-entry)
```

### 2.2 Key Variables

| Variable | Type | Description |
|----------|------|-------------|
| `country` | Categorical | 54 unique countries (anonymized) |
| `brand_name` | Categorical | 1,953 unique brands (anonymized) |
| `months_postgx` | Numeric | Months relative to generic entry (-24 to +23) |
| `volume` | Numeric | Monthly sales volume |
| `n_gxs` | Numeric | Number of generic competitors (0-43) |
| `ther_area` | Categorical | 14 therapeutic areas |
| `biological` | Binary | 1 if biological drug, 0 if small molecule |
| `hospital_rate` | Numeric | % of sales through hospital channel |
| `avg_vol` / `avg_j` | Numeric | Pre-entry average volume (baseline) |
| `vol_norm` | Numeric | Normalized volume (volume / avg_j) |
| `bucket` | Binary | 1 = high erosion, 2 = low erosion |

### 2.3 Missing Values Analysis

- **`time_to_50pct`**: Many brands (especially Bucket 2) never reach 50% erosion
- This results in `NaN` values for time_to_50pct metric
- **Recommendation**: Use median imputation or create binary flag for "never reached 50%"

---

## 3. Bucket Distribution Analysis

### 3.1 Distribution Summary

| Bucket | Count | Percentage | Weight | Effective Weight |
|--------|-------|------------|--------|------------------|
| **Bucket 1** (High Erosion) | 130 | 6.7% | 2√ó | 13.4% |
| **Bucket 2** (Low Erosion) | 1,823 | 93.3% | 1√ó | 86.6% |

### 3.2 Bucket Definitions

- **Bucket 1**: Mean normalized volume ‚â§ 0.25 in months 18-23 (75%+ volume loss)
- **Bucket 2**: Mean normalized volume > 0.25 in months 18-23

### 3.3 Imbalance Analysis

```
Imbalance Ratio: 14.02:1 (Bucket 2 : Bucket 1)
```

**‚ö†Ô∏è CRITICAL**: This severe imbalance requires special handling:
- Standard models will bias toward Bucket 2
- Bucket 1 predictions carry 2√ó weight in scoring
- Optimizing only for accuracy will hurt competition score

---

## 4. Erosion Curves by Bucket

### 4.1 Bucket 1 Erosion Profile (High Erosion)

| Metric | Month 0 | Month 6 | Month 12 | Month 23 |
|--------|---------|---------|----------|----------|
| Mean Vol Norm | 0.648 | 0.162 | 0.108 | 0.076 |
| Std Dev | 0.285 | 0.107 | 0.126 | 0.070 |

**Key Observations:**
- **Initial Drop**: 35% erosion by month 0 (from avg baseline of 1.0)
- **First 6 Months**: Drops from 0.65 to 0.16 (75% of total erosion!)
- **Stabilization**: Levels off around 0.08 by month 12
- **Final Level**: ~7.6% of original volume remains

### 4.2 Bucket 2 Erosion Profile (Low Erosion)

| Metric | Month 0 | Month 6 | Month 12 | Month 23 |
|--------|---------|---------|----------|----------|
| Mean Vol Norm | 0.864 | 0.697 | 0.582 | 0.517 |
| Std Dev | 0.171 | 0.249 | 0.255 | 0.287 |

**Key Observations:**
- **Initial Drop**: Only 14% erosion by month 0
- **Gradual Decline**: Steady erosion over 24 months
- **Higher Variability**: Std dev increases over time
- **Final Level**: ~52% of original volume remains

### 4.3 Monthly Erosion Rates

| Bucket | Mean Monthly Decline | Total 24-Month Loss |
|--------|---------------------|---------------------|
| Bucket 1 | -2.49% | 88.27% |
| Bucket 2 | -1.51% | 40.17% |

**Bucket 1 erodes 65% faster per month than Bucket 2**

---

## 5. Competition Impact Analysis

### 5.1 Generic Competitor Trajectory

| Time Point | Mean n_gxs | Std Dev |
|------------|-----------|---------|
| Month 0 (Entry) | 2.04 | 3.45 |
| Month 6 | 3.54 | 4.47 |
| Month 12 | 4.24 | 4.76 |
| Month 23 | 4.24 | 4.76 |

**Pattern**: Competition builds rapidly in first 12 months, then stabilizes.

### 5.2 Volume vs Number of Competitors

| n_gxs | Mean Vol Norm | Observation |
|-------|---------------|-------------|
| 0 | 0.785 | No competition yet |
| 1 | 0.633 | First generic entry |
| 2 | 0.577 | Two competitors |
| 3 | 0.554 | Three competitors |
| 4 | 0.519 | Four competitors |
| 5 | 0.497 | Five competitors |
| 6 | 0.436 | Six competitors |
| 10+ | ~0.45 | Diminishing returns |

**Key Insight**: Volume drops rapidly with first 6 competitors, then plateaus.

### 5.3 Competition Impact Curve

```
n_gxs:    0 ‚Üí 1 ‚Üí 2 ‚Üí 3 ‚Üí 4 ‚Üí 5 ‚Üí 6 ‚Üí 10+
vol_norm: 0.78 ‚Üí 0.63 ‚Üí 0.58 ‚Üí 0.55 ‚Üí 0.52 ‚Üí 0.50 ‚Üí 0.44 ‚Üí ~0.45
          ‚Üì 19%  ‚Üì 9%   ‚Üì 5%   ‚Üì 6%   ‚Üì 4%   ‚Üì 12%   plateau
```

**Recommendation**: Log-transform n_gxs to capture diminishing marginal impact.

---

## 6. Therapeutic Area Analysis

### 6.1 Erosion by Therapeutic Area (Ranked)

| Rank | Therapeutic Area | Mean Vol Norm | Erosion Level |
|------|-----------------|---------------|---------------|
| 1 | Anti-infectives | 0.515 | üî¥ Highest |
| 2 | Antineoplastic & Immunology | 0.551 | üî¥ High |
| 3 | Musculoskeletal/Rheumatology | 0.557 | üî¥ High |
| 4 | Parasitology | 0.591 | üü° Medium |
| 5 | Cardiovascular/Metabolic | 0.592 | üü° Medium |
| 6 | Haematology | 0.597 | üü° Medium |
| 7 | Nervous System | 0.607 | üü° Medium |
| 8 | Obstetrics/Gynaecology | 0.609 | üü° Medium |
| 9 | Systemic Hormones | 0.628 | üü° Medium |
| 10 | Others | 0.630 | üü° Medium |
| 11 | Dermatology | 0.644 | üü¢ Low |
| 12 | Endocrinology/Metabolic | 0.665 | üü¢ Low |
| 13 | Respiratory/Immuno-inflammatory | 0.698 | üü¢ Low |
| 14 | Sensory Organs | 0.725 | üü¢ Lowest |

### 6.2 Key Therapeutic Area Insights

**High Erosion Areas** (Mean < 0.56):
- Anti-infectives: Highly substitutable antibiotics
- Oncology/Immunology: High-cost specialty drugs with biosimilar pressure
- Musculoskeletal: Generic-friendly pain medications

**Low Erosion Areas** (Mean > 0.65):
- Sensory Organs: Specialized formulations, patient loyalty
- Respiratory: Complex delivery systems (inhalers)
- Endocrinology: Chronic conditions, switching costs

**Range**: 0.515 to 0.725 (21 percentage points spread)

---

## 7. Biological vs Small Molecule

### 7.1 Comparison Summary

| Drug Type | Mean Vol Norm | Final Vol (M23) | Total Erosion |
|-----------|--------------|-----------------|---------------|
| Small Molecule | 0.593 | 0.487 | 42.57% |
| Biological | 0.619 | 0.488 | 42.87% |

### 7.2 Key Finding

**Surprisingly similar erosion patterns!**

- Both drug types show nearly identical total erosion (~42.7%)
- Biological drugs have slightly higher mean during erosion period
- Final equilibrium is virtually the same (0.487 vs 0.488)

**Possible Explanations:**
1. Biosimilars have become competitive with generics
2. Dataset may include newer biosimilar-exposed biologics
3. Price pressure affects both categories similarly

**Recommendation**: `biological` feature has **limited predictive power** for final erosion level.

---

## 8. Hospital Rate Impact

### 8.1 Erosion by Hospital Distribution

| Hospital Rate | Month 0 | Month 12 | Month 23 | Pattern |
|--------------|---------|----------|----------|---------|
| **0-25%** (Retail) | 0.874 | 0.584 | 0.509 | Moderate erosion |
| **25-50%** | 0.871 | 0.627 | 0.556 | Slowest erosion |
| **50-75%** | 0.853 | 0.627 | 0.485 | Moderate erosion |
| **75-100%** (Hospital) | 0.849 | 0.554 | 0.446 | **Fastest erosion** |

### 8.2 Key Insights

**High Hospital Rate (75-100%) Shows:**
- Faster initial erosion (hospital tender processes)
- Lower final equilibrium (0.446 vs 0.509-0.556)
- More price-sensitive purchasing decisions

**Low Hospital Rate (0-25%) Shows:**
- Slower erosion trajectory
- Higher final volume retention
- Patient/prescriber loyalty matters more

**Recommendation**: Create hospital_rate_bucket feature for better segmentation.

---

## 9. Erosion Speed Metrics

### 9.1 Time to 50% Volume

| Bucket | Mean (months) | Median (months) | Min | Max |
|--------|---------------|-----------------|-----|-----|
| Bucket 1 | 1.37 | 1.0 | 0 | 6 |
| Bucket 2 | 7.92 | 6.5 | 0 | 23 |

**Bucket 1 reaches 50% erosion 5.8√ó faster than Bucket 2**

### 9.2 First 6 Months Erosion Rate

| Bucket | Mean Erosion (6m) | Median |
|--------|------------------|--------|
| Bucket 1 | 66.7% | 68.3% |
| Bucket 2 | 24.3% | 21.1% |

**Bucket 1 loses 2.7√ó more volume in first 6 months**

### 9.3 Final Equilibrium (Months 18-23)

| Bucket | Mean Final Vol | Median |
|--------|---------------|--------|
| Bucket 1 | 0.077 | 0.063 |
| Bucket 2 | 0.529 | 0.539 |

**Bucket 1 final level is 6.9√ó lower than Bucket 2**

---

## 10. Key Patterns & Insights

### 10.1 Temporal Patterns

```
EROSION TIMELINE
================
Month 0-3:   Rapid initial drop (most critical period)
Month 3-6:   Continued steep decline
Month 6-12:  Erosion slows, pattern emerges
Month 12-18: Approaching equilibrium
Month 18-23: Stable equilibrium level

üéØ CRITICAL INSIGHT: First 6 months determine bucket membership!
```

### 10.2 Feature Importance Hierarchy (Expected)

Based on EDA, expected feature importance:

1. **`months_postgx`** - Time is primary driver
2. **`n_gxs`** - Competition pressure (diminishing returns)
3. **`ther_area`** - Strong category effects
4. **`hospital_rate`** - Distribution channel impact
5. **`avg_vol` / `avg_j`** - Baseline volume matters
6. **`biological`** - Limited impact on final erosion

### 10.3 Bucket Prediction Signals

**Early Bucket 1 Signals:**
- Sharp initial drop (>40% in month 0)
- Rapid competition buildup
- Anti-infectives or Oncology therapeutic area
- High hospital rate (>75%)

**Bucket 2 Signals:**
- Gradual initial decline (<20% in month 0)
- Lower competition
- Sensory organs, Respiratory areas
- Lower hospital rate

---

## 11. Data Preprocessing Recommendations

### 11.1 Missing Value Handling

| Issue | Recommended Action |
|-------|-------------------|
| `time_to_50pct` is NaN for brands never reaching 50% | Impute with 24 (max months) or create binary flag `reached_50pct` |
| Missing `avg_vol` for some test brands | Use training median or predict from features |

### 11.2 Outlier Treatment

| Variable | Outlier Pattern | Recommendation |
|----------|-----------------|----------------|
| `n_gxs` | Few brands with 30-43 competitors | Cap at 15 (99th percentile) |
| `vol_norm` | Some values > 1.0 (growth cases) | Keep, but flag for analysis |
| `volume` | High variance across brands | Use normalized volume instead |

### 11.3 Feature Scaling

```python
# Recommended scaling strategy
scaling_strategy = {
    'months_postgx': 'StandardScaler',    # Already bounded, center important
    'n_gxs': 'Log1p + StandardScaler',    # Diminishing returns pattern
    'hospital_rate': 'None or MinMax',    # Already 0-1 range
    'avg_vol': 'Log + StandardScaler',    # High variance
    'vol_norm': 'None',                   # Target-related, keep as-is
}
```

### 11.4 Categorical Encoding

| Variable | Recommended Encoding |
|----------|---------------------|
| `country` | Target encoding (mean vol_norm) |
| `ther_area` | Target encoding or ordinal (by erosion rank) |
| `biological` | Keep binary (0/1) |
| `main_package` | Target encoding |

---

## 12. Feature Engineering Recommendations

### 12.1 Time-Based Features

```python
# Essential time features
time_features = {
    'months_postgx_squared': 'months_postgx ** 2',  # Capture non-linear decay
    'months_postgx_sqrt': 'sqrt(months_postgx)',    # Early period emphasis
    'is_early_period': 'months_postgx <= 6',        # Critical first 6 months
    'is_late_period': 'months_postgx >= 18',        # Equilibrium period
    'time_bucket': 'pd.cut(months_postgx, [0,6,12,18,24])',  # Time segments
}
```

### 12.2 Competition Features

```python
# Competition-based features
competition_features = {
    'log_n_gxs': 'np.log1p(n_gxs)',                # Diminishing returns
    'n_gxs_squared': 'n_gxs ** 2',                 # Non-linear impact
    'has_competition': 'n_gxs > 0',                # Binary flag
    'high_competition': 'n_gxs >= 5',              # Threshold flag
    'competition_intensity': 'n_gxs / (months_postgx + 1)',  # Rate of buildup
}
```

### 12.3 Lag Features (Critical for Time Series)

```python
# Lag features for volume trajectory
lag_features = {
    'vol_norm_lag1': 'Previous month volume',
    'vol_norm_lag3': '3-month lag',
    'vol_norm_lag6': '6-month lag',
    'vol_norm_diff1': 'Month-over-month change',
    'vol_norm_diff3': '3-month change',
    'vol_norm_pct_change': 'Percentage change',
}
```

### 12.4 Rolling Statistics

```python
# Rolling window features
rolling_features = {
    'vol_norm_rolling_mean_3': '3-month rolling average',
    'vol_norm_rolling_mean_6': '6-month rolling average',
    'vol_norm_rolling_std_3': '3-month rolling std',
    'vol_norm_rolling_min_6': '6-month rolling minimum',
    'erosion_rate_3m': 'Erosion rate over last 3 months',
}
```

### 12.5 Interaction Features

```python
# High-value interaction features
interaction_features = {
    'time_x_competition': 'months_postgx * n_gxs',
    'time_x_hospital': 'months_postgx * hospital_rate',
    'competition_x_hospital': 'n_gxs * hospital_rate',
    'early_high_competition': 'is_early_period * high_competition',
}
```

### 12.6 Category-Based Features

```python
# Category-derived features
category_features = {
    'ther_area_erosion_rank': 'Ordinal ranking by mean erosion',
    'ther_area_mean_erosion': 'Target-encoded therapeutic area',
    'country_mean_erosion': 'Target-encoded country',
    'is_high_erosion_area': 'ther_area in [Anti-infectives, Oncology, MSK]',
}
```

---

## 13. Modeling Recommendations

### 13.1 Handling Class Imbalance

**Critical**: Bucket 1 is only 6.7% of data but has 2√ó weight!

**Recommended Approaches:**

1. **Stratified Sampling**
   ```python
   # Use stratified K-fold
   from sklearn.model_selection import StratifiedKFold
   skf = StratifiedKFold(n_splits=5, shuffle=True, random_state=42)
   ```

2. **Sample Weights**
   ```python
   # Weight Bucket 1 samples higher
   sample_weight = df['bucket'].map({1: 2.0, 2: 1.0})
   model.fit(X, y, sample_weight=sample_weight)
   ```

3. **Oversampling Bucket 1**
   ```python
   # SMOTE for Bucket 1 brands
   from imblearn.over_sampling import SMOTE
   X_res, y_res = SMOTE().fit_resample(X, y_bucket)
   ```

4. **Separate Models Per Bucket**
   ```python
   # Train bucket classifier first, then separate regressors
   bucket_classifier.fit(X, y_bucket)
   bucket1_model.fit(X[bucket==1], y[bucket==1])
   bucket2_model.fit(X[bucket==2], y[bucket==2])
   ```

### 13.2 Model Selection

| Model Type | Strengths | Use Case |
|------------|-----------|----------|
| **Exponential Decay** | Captures physics of erosion | Baseline, interpretable |
| **LightGBM/XGBoost** | Handles non-linearity, interactions | Primary ML model |
| **Hybrid (Physics+ML)** | Physics baseline + ML residuals | Best of both worlds |
| **ARIHOW (SARIMAX+HW)** | Time series patterns | Per-brand forecasting |

### 13.3 Cross-Validation Strategy

```python
# Recommended CV approach
cv_strategy = {
    'type': 'GroupKFold',           # Group by brand to prevent leakage
    'n_splits': 5,
    'stratify_by': 'bucket',        # Ensure both buckets in each fold
    'time_aware': True,             # Don't use future to predict past
}
```

### 13.4 Evaluation Metrics

| Metric | Purpose | Weight |
|--------|---------|--------|
| **WMAPE** (Scenario metric) | Primary competition metric | 100% |
| **MAE by Bucket** | Ensure Bucket 1 not ignored | Diagnostic |
| **MAE by Time Period** | Check early vs late prediction quality | Diagnostic |

### 13.5 Ensemble Strategy

```python
# Recommended ensemble
ensemble = {
    'baseline_exp_decay': 0.3,      # Physics-based foundation
    'hybrid_lightgbm': 0.4,         # Primary ML model
    'arihow': 0.3,                  # Time series component
}
```

### 13.6 Post-Processing

1. **Clip Predictions**: Ensure vol_norm ‚àà [0, 1.5]
2. **Monotonicity**: Enforce non-increasing volume (optional)
3. **Bucket-Specific Adjustments**: Scale predictions if bucket predictions systematically biased

---

## üìù Summary: Top 10 Action Items

| Priority | Action | Impact |
|----------|--------|--------|
| üî¥ 1 | Handle Bucket 1 imbalance (sample weights or separate models) | Critical |
| üî¥ 2 | Create lag features (vol_norm_lag1, lag3, lag6) | High |
| üî¥ 3 | Add rolling statistics (3m, 6m windows) | High |
| üü° 4 | Log-transform n_gxs to capture diminishing returns | Medium |
| üü° 5 | Target-encode therapeutic area by erosion rank | Medium |
| üü° 6 | Create time buckets (0-6, 6-12, 12-18, 18-24) | Medium |
| üü° 7 | Add erosion rate features (month-over-month change) | Medium |
| üü¢ 8 | Cap n_gxs at 15 (outlier handling) | Low |
| üü¢ 9 | Create hospital_rate buckets (4 levels) | Low |
| üü¢ 10 | Add interaction features (time √ó competition) | Low |

---

## üìö Appendix: Data Files

| File | Description |
|------|-------------|
| `fig01_bucket_distribution.json/csv` | Bucket counts and percentages |
| `fig02_erosion_curves.json/csv` | Monthly vol_norm by bucket |
| `fig03_sample_trajectories.json/csv` | Individual brand examples |
| `fig04_competition_impact.json` | n_gxs vs vol_norm analysis |
| `fig04_n_gxs_impact.csv` | Detailed competition data |
| `fig04_competition_trajectory.csv` | n_gxs over time |
| `fig05_therapeutic_areas.json/csv` | Erosion by ther_area |
| `fig06_biological_vs_small.json/csv` | Drug type comparison |
| `fig07_hospital_rate.json/csv` | Hospital channel impact |
| `fig08_erosion_speed.json` | Speed metrics summary |
| `fig08_erosion_speed_full.csv` | Per-brand erosion metrics |
| `eda_complete_summary.json` | Full EDA summary |

---

*Report generated from EDA data files in `reports/eda_data/`*
